Amgen Inc Drug Patent Portfolio
Amgen Inc owns 3 orange book drugs protected by 27 US patents Given below is the complete list of Amgen Inc's drugs and the patents protecting them.
1. Corlanor
Corlanor is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7867996
(Pediatric)
| γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
12 Jun, 2027
(2 years from now)
| Active |
| US7867996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
12 Dec, 2026
(2 years from now)
| Active |
| US7361649
(Pediatric)
| β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Aug, 2026
(1 year, 11 months from now)
| Active |
| US7361650
(Pediatric)
| γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Aug, 2026
(1 year, 11 months from now)
| Active |
| US7879842
(Pediatric)
| Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Aug, 2026
(1 year, 11 months from now)
| Active |
| US7361649 | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Feb, 2026
(1 year, 5 months from now)
| Active |
| US7361650 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Feb, 2026
(1 year, 5 months from now)
| Active |
| US7879842 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Feb, 2026
(1 year, 5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Corlanor's drug page
2. Lumakras
Lumakras is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11426404 | Dosing of KRAS inhibitor for treatment of cancers |
15 Sep, 2040
(15 years from now)
| Active |
| US11236091 | Solid state forms |
20 May, 2040
(15 years from now)
| Active |
| US11827635 | Solid state forms |
20 May, 2040
(15 years from now)
| Active |
| US10519146 | KRAS G12C inhibitors and methods of using the same |
21 May, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumakras's drug page
3. Otezla
Otezla is protected by 15 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10092541
(Pediatric)
| Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
29 Nov, 2034
(10 years from now)
| Active |
| US9872854
(Pediatric)
| Methods for the treatment of psoriatic arthritis using apremilast |
29 Nov, 2034
(10 years from now)
| Active |
| US10092541 | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
29 May, 2034
(9 years from now)
| Active |
| US9872854 | Methods for the treatment of psoriatic arthritis using apremilast |
29 May, 2034
(9 years from now)
| Active |
| US7427638
(Pediatric)
| (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
16 Aug, 2028
(3 years from now)
| Active |
| US7427638 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
16 Feb, 2028
(3 years from now)
| Active |
| US7893101 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
09 Dec, 2023
(9 months ago)
| Expired |
| US6962940 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US7208516 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US7659302 | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US8455536 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US8802717 | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US9018243 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US9724330 | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
19 Mar, 2023
(1 year, 6 months ago)
| Expired |
| US6020358 | Substituted phenethylsulfones and method of reducing TNFα levels |
30 Oct, 2018
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Otezla's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List